MALAT1 and breast carcinoma: There are also several studies supporting MALAT1 expression as a clinical biomarker mainly associated with a poor prognosis in solid tumors3, although in some neoplasms such as diffuse large B-cell lymphoma (DLBCL), colorectal and breast cancer, high levels of MALAT1 have been linked to a favorable outcome5–7.